Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 8, Issue 7, Pages 1052-1069Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2012.02.009
Keywords
Neurorestoration; Neuroprotection; Neurodegeneration; Regeneration; Survival
Funding
- Consejo Nacional de Ciencia y Tecnologia de Mexico [83229]
- Instituto Cientifico Pfizer
- Canadian Institutes of Health Research [OPD-79574, MOP-49591, MOP-106556]
- Parkinson Society Canada
- National Institutes of Health [DA006470]
- Consejo Nacional de Ciencia y Tecnologia de Mexico
Ask authors/readers for more resources
Nanomedicine has focused on targeted neurotrophic gene delivery to the brain as a strategy to stop and reverse neurodegeneration in Parkinson's disease. Because of improved transfection ability, synthetic nanocarriers have become candidates for neurotrophic therapy. Neurotensin (NTS)-polyplex is a Trojan horse synthetic nanocarrier system that enters dopaminergic neurons through NTS receptor internalization to deliver a genetic cargo. The success of preclinical studies with different neurotrophic genes supports the possibility of using NTS-polyplex in nanomedicine. In this review, we describe the mechanism of NTS-polyplex transfection. We discuss the concept that an effective neurotrophic therapy requires a simultaneous effect on the axon terminals and soma of the remaining dopaminergic neurons. We also discuss the future of this strategy for the treatment of Parkinson's disease. From the Clinical Editor: This review paper focuses on nanomedicine-based treatment of Parkinson's disease, a neurodegenerative condition with existing symptomatic but no curative treatment. Neurotensin-polyplex is a synthetic nanocarrier system that enables delivery of genetic cargo to dopaminergic neurons via NTS receptor internalization. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available